Studienlage · Detail
Klarer Nutzen
GRADE
Hoch
1543 Zitate
Stichproben = 562 Pat.
Dauer2000 bis 2006
KontrolleKrebsfreie Kontrollpersonen, individuell…
EndpunktOR für HPV-16-pos./neg. HNSCC
Verblindungn.a.
DesignFall-Kontroll-Studie (krankenhaus-basiert)
Applikationinhalativ
Kernaussage
Cannabis-Konsum ist ein unabhängiger Risikofaktor für HPV-16-positive, nicht jedoch für HPV-16-negative Kopf-Hals-Karzinome.
Zusammenfassung
Fall-Kontroll-Studie (n=240 HNSCC-Fälle, n=322 Kontrollen): Cannabiskonsum war unabhängig mit HPV-16-positivem Kopf-Hals-Plattenepithelkarzinom assoziiert — dosisabhängig steigend mit Intensität (Joints/Monat, p(trend)=0,007), Dauer (Jahre, p(trend)=0,01) und kumulativen Joint-Jahren (p(trend)=0,003). Für HPV-16-negative HNSCC kein Zusammenhang mit Cannabiskonsum (OR nicht signifikant). Befunde deuten auf Cannabis-assoziiertes Krebsrisiko spezifisch im HPV-16-positiven HNSCC-Subtyp.
P
PopulationPatienten mit Kopf-Hals-Plattenepithelkarzinom (HNSCC), n=240 Fälle (92 HPV-16-positiv, 148 HPV-16-negativ) und n=322 Kontrollen ohne Krebs, rekrutiert am Johns Hopkins Hospital 2000–2006
I
InterventionExposition gegenüber Cannabis-Konsum (Intensität, Dauer, kumulativer Gebrauch in Joint-Jahren) sowie sexuellem Verhalten (orale Sexualpartner)
C
KontrolleKrebsfreie Kontrollpersonen, individuell nach Alter und Geschlecht gematcht
O
OutcomeCannabis-Konsum unabhängig mit HPV-16-positivem HNSCC assoziiert (Trend für kumulative Joint-Jahre p=0.003); kein Zusammenhang mit Tabak/Alkohol für HPV-16-positives HNSCC; HPV-16-negatives HNSCC mit Tabak (≥20 Packungsjahre + Alkohol: OR=4.8, 95%-KI 1.8–12), Alkohol und schlechter Mundhygiene assoziiert, nicht mit sexuellem Verhalten oder Cannabis
Vertrauen in die Evidenz
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
Qualitätsprofil
Größe
★★★★★
Verblindung
—
Effektstärke
Klarer Nutzen
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
<h4>Background</h4>High-risk types of human papillomavirus (HPV), including HPV-16, cause a subgroup of head and neck squamous cell carcinomas (HNSCCs). We examined whether the risk factors for HPV-16-positive HNSCCs are similar to those for HPV-16-negative HNSCCs in a hospital-based case-control study.<h4>Methods</h4>Case subjects (n = 240) diagnosed with HNSCC at the Johns Hopkins Hospital from 2000 through 2006 were stratified by tumor HPV-16 status as determined by in situ hybridization. Two control subjects (n = 322) without cancer were individually matched by age and sex to each HPV-16-positive and HPV-16-negative case subject. Data on risk behaviors were obtained by use of audio computer-assisted self-interview technology. Multivariable conditional logistic regression models were used to estimate the odds ratios (ORs) for HPV-16-positive HNSCC and HPV-16-negative HNSCC associated with risk factors. All statistical tests were two-sided.<h4>Results</h4>HPV-16 was detected in 92 of 240 case subjects. HPV-16-positive HNSCC was independently associated with several measures of sexual behavior and exposure to Cannabis but not with cumulative measures of tobacco smoking, alcohol drinking, or poor oral hygiene. Associations increased in strength with increasing number of oral sex partners (P(trend) = .01) and with increasing intensity (joints per month, P(trend) = .007), duration (in years, P(trend) = .01), and cumulative joint-years (P(trend) = .003) of Cannabis use. By contrast, HPV-16-negative HNSCC was associated with measures of tobacco smoking, alcohol drinking, and poor oral hygiene but not with any measure of sexual behavior or Cannabis use. Associations increased in strength with increasing intensity (cigarettes per day), duration, and cumulative pack-years of tobacco smoking (for all, P(trend) < .001), increasing years of heavy alcohol drinking (> or = 15 years of 14 drinks per week; P(trend) = .03), and increasing number of lost teeth (P(trend) = .001). Compared with subjects who neither smoked tobacco nor drank alcohol, those with heavy use of tobacco (> or = 20 pack-years) and alcohol had an increased risk of HPV-16-negative HNSCC (OR = 4.8, 95% confidence interval [CI] = 1.8 to 12) but not of HPV-16-positive HNSCC (OR = 0.67, 95% CI = 0.29 to 1.9).<h4>Conclusions</h4>HPV-16-positive HNSCCs and HPV-16-negative HNSCCs have different risk factor profiles, indicating that they should be considered to be distinct cancers.
„Was dem Handeln im Weg steht, wird zum Weg.“